KOL Perspectives: Implementation of the treattotarget approach in IBD
Summary
This KOL Insight briefing focuses on KOLs views of implementation of the treattotarget approach in IBD.
The briefing includes analysis of KOL opinion on the following topic areas
Perceptions of the CALM study and potential impact on Crohn's disease clinical management
Adoption of a T2T approach in UC
Impact of T2T studies on choice of therapy
Monitoring mucosal healing in IBD
Key Highlights
Most KOLs view the data from the CALM study as supportive of the concept of a T2T strategy in Crohn's disease
T2T is used routinely in clinical practice, with an increase in a patient's disease severity used as a driver for adoption of the strategy
Over half the KOLs expect the CALM study to positively influence Crohn's disease management across clinical practice.
Scope
The insight briefing is based on Sociable Pharma's analysis of primary research with our inflammatory bowel disease key opinion leaders KOLs
In total, we conducted interviews with 10 KOLs: 5 Europebased 5 N. Americabased
Interviews performed during December 2017
KOL data is analyzed to produce: Charts summarizing KOL opinions
Chart callouts of key information details
KOL quotes
Summary of KOL reporting trends
Insight from Sociable Pharma's analysts.
Reasons to buy
Combines Qualitative semiquantitative insight from key opinion leaders on "implementation of a treattotarget T2T approach in IBD"
Includes insight recommendations from our diseasespecific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of IBD
Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.